Aditx Therapeutics (ADTX)
(Real Time Quote from BATS)
$1.72 USD
+0.03 (1.78%)
Updated Jul 10, 2024 10:34 AM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ADTX 1.72 +0.03(1.78%)
Will ADTX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ADTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADTX
Indivior PLC (INDV) Tops Q3 Earnings and Revenue Estimates
Marinus Pharmaceuticals (MRNS) Reports Q2 Loss, Tops Revenue Estimates
ADTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Harpoon Therapeutics, Inc. (HARP) Beats Q2 Earnings and Revenue Estimates
Xencor (XNCR) Reports Q2 Loss, Tops Revenue Estimates
Is the Options Market Predicting a Spike in Aditx (ADTX) Stock?
Other News for ADTX
ADTX Stock Earnings: Aditxt Reported Results for Q1 2024
Aditxt prices $4.2M private placement
CORRECTING and REPLACING Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq Rules
Aditxt, Inc. Merger with Evofem Biosciences Falls Through